Experts discuss the pivotal role of ctDNA in postoperative colorectal cancer care, using it alongside pathology and staging to personalize recurrence...

Declan Walsh, MD, highlighted how the supportive and palliative care space has evolved since he first began working in the field.

Panelists discuss how the CARTITUDE-4 clinical trial demonstrated that ciltacabtagene autoleucel (cilta-cel) chimeric antigen receptor (CAR) T-cell th...

Panelists discuss how current chimeric antigen receptor (CAR) T therapies for early relapsed/refractory multiple myeloma (R/R MM) include both ciltaca...

Experts discuss how postoperative surveillance after colorectal cancer surgery is increasingly personalized by integrating pathologic staging, surgica...

The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.

Results from a pilot phase 2 trial showed that all 5 patients who received treatment achieved a response or had stable disease.

Data from KEYNOTE-585 showed that adding pembrolizumab to chemotherapy did not negatively impact health-related quality of life vs placebo/chemotherap...

Boris M. Kiselev, MD, explores evidence-based interventions for managing cancer-related anxiety and depression.

TAS-102 had a significant impact, achieving ctDNA clearance, in patients with colorectal cancer with ctDNA-defined MRD.